Here's Why Haemonetics (HAE) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Earn Twice The Yield You Get From Bank On HAE Stock
Currently priced at approximately $80.53 per share, Haemonetics (NYSE: HAE) is trading roughly 7.6% below its 52-week high.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Haemonetics (HAE) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is it Apt to Retain Haemonetics Stock in Your Portfolio Now?
HAE's Hospital rebound and rising NexSys PCS adoption boost growth prospects despite FX and solvency pressures.
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating
I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout, supporting a high probability of success of 90%+ (author's judgement).
Interpreting Haemonetics (HAE) International Revenue Trends
Review Haemonetics' (HAE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
